Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
MALVERN, Pa., April 24, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biotechnology company focused on defining new standards of care in medical and aesthetic dermatology, today announced it will sponsor a symposium on Janus Kinase (JAK) inhibitors at the 76th Annual Society for Investigative Dermatology Meeting in Portland, Oregon. The symposium, titled “You Don’t Know JAK,” will be held on Thursday, April 27, 2017, from 12:00-1:45 PM PST. Poster presentations include:
- Clinical investigation of JAK inhibitor tofacitinib in scarring alopecias: Lindsey Bordone, MD, Columbia University, New York, NY, Abstract #075
- Treatment of vitiligo with topical Janus Kinase inhibitor ruxolitinib: Brooke Rothstein, Tufts Medical Center, Boston, MA, Abstract #770
- Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials: James Chen, PhD, Columbia University, New York, NY, Abstract #397
Dr. Neal Walker, President and Chief Executive Officer, and Dr. Stuart Shanler, Chief Scientific Officer, will be in attendance. Following the poster presentations, there will be a panel discussion and question and answer session with presenters.
Additional information on the 76th Annual Society of Investigative Dermatology Meeting can be found at: http://www.sidnet.org/news/339026/View-the-2017-Annual-Meeting-Program.htm
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
